Brandon T Gufford - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Brandon T Gufford

Showing results (21-30 of 26) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 26 results.

Clinical Pharmacology and Therapeutics|September 30, 2017

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAsKimberly S Burgess, Joseph Ipe, Marelize Swart, et al.

AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019

Developing User Personas to Aid in the Design of a User-Centered Natural Product-Drug Interaction Information Resource for ResearchersRichard D Boyce, Isabelle Ragueneau-Majlessi, Jingjing Yu, et al.

Pharmacogenomics|February 21, 2019

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trialCathy R Fulton, Yong Zang, Zeruesenay Desta, et al.

Cancer|January 23, 2024

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.

The Pharmacogenomics Journal|September 9, 2023

The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trialMichael T Eadon, Marc B Rosenman, Pengyue Zhang, et al.

Clinical Pharmacology and Therapeutics|July 26, 2024

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy VolunteersShruti M Raja, Jeffrey T Guptill, Michelle Mack, et al.

Pageof 3

Search research articles

Showing results (21-30 of 26) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 26 results.

Clinical Pharmacology and Therapeutics|September 30, 2017

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAsKimberly S Burgess, Joseph Ipe, Marelize Swart, et al.

AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019

Developing User Personas to Aid in the Design of a User-Centered Natural Product-Drug Interaction Information Resource for ResearchersRichard D Boyce, Isabelle Ragueneau-Majlessi, Jingjing Yu, et al.

Pharmacogenomics|February 21, 2019

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trialCathy R Fulton, Yong Zang, Zeruesenay Desta, et al.

Cancer|January 23, 2024

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.

The Pharmacogenomics Journal|September 9, 2023

The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trialMichael T Eadon, Marc B Rosenman, Pengyue Zhang, et al.

Clinical Pharmacology and Therapeutics|July 26, 2024

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy VolunteersShruti M Raja, Jeffrey T Guptill, Michelle Mack, et al.

Pageof 3